预约演示
更新于：2025-10-22
Mupirocin
莫匹罗星
更新于：2025-10-22
概要
基本信息
简介莫匹罗星（Mupirocin）商品名CENTANY®，是一种小分子药物，通过抑制RNA合成酶治疗由革兰氏阳性细菌引起的脓疱病和其他皮肤感染。Mupirocin最初由GSK开发，1987年12月首次批准使用。CENTANY®软膏是一种局部药物，用于通过抑制细菌生长和阻止感染传播来治疗脓疱病。 |
药物类型 小分子化药 |
别名 Bactroban Nasal、Mupirocin (USP/INN)、Mupirocin cream + [6] |
作用方式 抑制剂 |
作用机制 Bacterial IRS抑制剂(细菌异硫氨酸-tRNA合成酶抑制剂) |
非在研适应症- |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C26H44O9 |
InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N |
CAS号12650-69-0 |
关联
84
项与 莫匹罗星 相关的临床试验NCT06712433
Bacterial Decolonization Plus Intraoperative Indocyanine Green Angiography for Soft Tissue Sarcomas of the Lower Extremity Receiving Preoperative Radiotherapy (CONCERTO)
NCT06541145
Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads
NCT06210594
SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease Staphylococcus Aureus Carriage in Adults
100 项与 莫匹罗星 相关的临床结果
登录后查看更多信息
100 项与 莫匹罗星 相关的转化医学
登录后查看更多信息
100 项与 莫匹罗星 相关的专利（医药）
登录后查看更多信息
2,656
项与 莫匹罗星 相关的文献（医药）2025-12-01Biomaterials advances
Porous hydrogel of siloxane-modified polyvinyl alcohol/polydopamine containing berberine chloride, exhibiting robust antibacterial activity and promoting the healing of MRSA-infected wounds
Article
作者: Hamishehkar, Hamed ; Farahpour, Mohammad Reza ; Kiumarsi, Amirhossein ; Tabatabaei, Zohreh Ghazi
Advanced and novel effective wound dressings that decrease wound infections are essential for clinical application. In this study, a multifunctional hydrogel was engineered based on polyvinyl alcohol (PVA), polydopamine (PDA), and porous silica (PSi), loaded with berberine chloride (Bbn), for the treatment of MRSA-infected wounds. The PVA@PSi/PDA-Bbn hydrogel was fabricated via sol-gel and self-polymerization methods, forming a porous, adhesive, and photothermal-responsive matrix. The hydrogel demonstrated excellent swelling behavior, mechanical strength, and sustained Bbn release under NIR irradiation. The efficacy of the hydrogels was evaluated through antibacterial activity, pathological assessments, and the expression of key proteins involved in cell proliferation and wound healing. These proteins included cyclin D1, c-Myc, Max, FGF-1, β-catenin, and WNT-1, and COL1A. The physicochemical properties of the hydrogels confirmed their successful synthesis and suitability for biomedical applications. The results for swelling, rheological properties, adhesive strength, safety, and antibacterial activity confirmed the hydrogels to be appropriate. The PVA@PSi40/PAD-Bbn hydrogel could enhance the healing process through its antibacterial activity and modulation of the expressions of cyclin D1, c-Myc, Max, FGF-1, β-catenin, and COL1-A. In sum, PVA@PSi40/PAD-Bbn could compete with the mupirocin ointment® and accelerate the MRSA-wound healing process. It showed better performance than conventional treatments by providing controlled drug release, strong tissue adhesion, and effective MRSA inhibition to promote wound healing.
2025-11-01Current drug discovery technologies
Virtual Screening and Identification of Novel Oxindole Derivatives as Potential Antimicrobial Agents
Article
作者: Gnanavelou, Revathi ; Perinbaraj, Sowmiya ; Girija, Konda Reddy
Introduction::
Antimicrobial resistance (AMR), according to the World Health Organi-zation, is one of the most serious risks to global public health and development. It is a serious health hazard, with over 10 million deaths expected by 2050. New treatment materials and ways to remove AMR pathogens are in great demand to combat illnesses caused by such bacteria. Hence, the current work focused on virtual screening of the therapeutic potential of new oxindole derivatives against the targeted enzymes for antibacterial activity.
Materials and Methods::
A series of 120 novel 3-substituted-2-oxindole derivatives were designed based on the literature and SAR study, which were screened for their binding affinity against tar-geted enzymes, such as methionyl-tRNA synthetase (1PFV) and tyrosyl-tRNA synthetase (1JIL) using AutoDock Vina software. Compounds with significant binding energy were identified and filtered for appropriate ADME properties using the SwissADME program. Furthermore, the top fifteen hit compounds were evaluated for toxicity risk and drug score with the pkCSM online tool and OSIRIS Property Explorer, respectively.
Results and Discussion::
The docking analysis of the top two hits revealed that compounds 4 and 6 had a binding affinity of -10.1 Kcal/mol and -10.0 Kcal/mol against the targeted enzymes, respec-tively, compared to the standard (Tetracycline -9.3 Kcal/mol and Mupirocin -7.5 Kcal/mol).
Conclusion::
Hence, the best-hit compound 4 underwent MD simulation, validating its stability and successfully satisfying all in silico parameters, necessitating further synthesis and screening for in-vitro antimicrobial activity. These novel oxindole scaffolds could thus serve as promising leads for effective antibacterial drugs.
2025-11-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
A new efficient skin dressing based on sodium alginate − graphene oxide bionanocomposite hydrogel to expedite wound healing process
Article
作者: Naderi-Manesh, Hossein ; Rafati, Nesa
Wound management remains challenging due to the complex and multi-stage nature of healing process, making the selection of appropriate dressings critical for preventing infection and promoting tissue regeneration. In this study, an alginate-graphene oxide-mupirocin bionanocomposite hydrogel was developed as a multifunctional skin dressing to accelerate wound healing and provide antibacterial protection. The process involved the synthesis of graphene oxide followed by the preparation of graphene oxide and mupirocin-loaded sodium alginate hydrogels. Comprehensive structural characterizations were carried out using DLS, FTIR, FE-SEM, XRD, and TGA techniques. The hydrogel exhibited a highly porous structure, favorable for drug loading and water uptake, and demonstrated structural stability over a six-month storage period. Physicochemical and biological properties including swelling behavior, mechanical integrity, sustained drug release (up to 52 h), antibacterial activity, hemocompatibility, and cytocompatibility were systematically evaluated. The hydrogel effectively inhibited Staphylococcus aureus growth in vitro. Biocompatibility was confirmed through cell viability assays using L929 mouse fibroblasts and HU02 human fibroblasts, while hemocompatibility was assessed via hemolysis testing. In vivo studies demonstrated that the hydrogel markedly enhanced wound closure, attenuated inflammation, and facilitated tissue regeneration, resulting in complete healing within 16 days. These results highlight the potential of this bionanocomposite hydrogel as a promising platform for advanced wound care applications.
100 项与 莫匹罗星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 继发感染 | 澳大利亚 | 1998-04-03 | |
| 革兰氏阳性细菌感染 | 中国 | 1993-01-01 | |
| 脓疱疮 | 美国 | 1987-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 细菌感染 | 临床前 | 以色列 | 2025-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 14 | Hygiene education (Hygiene Education) | 窪齋襯鹹鹹壓繭鹹範鏇 = 鏇獵選膚積鹹衊網壓醖 鏇鑰觸構鬱鬱壓淵廠簾 (衊鬱鬱襯觸齋願積窪壓, 艱築簾願膚膚膚膚製窪 ~ 構鏇簾顧糧網範廠壓網) 更多 | - | 2024-06-25 | |
Sodium Hypochlorite+Mupirocin ointment (Hygiene Education and Decolonization) | 窪齋襯鹹鹹壓繭鹹範鏇 = 糧鏇齋糧膚鹹觸膚艱積 鏇鑰觸構鬱鬱壓淵廠簾 (衊鬱鬱襯觸齋願積窪壓, 鬱鹽糧遞鹹壓糧鬱觸築 ~ 鏇範憲衊襯憲鹹襯壓鹹) 更多 | ||||||
临床4期 | 353,323 | (Arm 1: Routine Care (Mupirocin/CHG)) | 夢範齋糧夢鹹餘構積鹽 = 觸衊糧築範襯築選鏇淵 範夢製壓鬱襯獵構顧淵 (廠願網鏇鏇壓糧壓廠衊, 遞衊範選醖願顧餘鹽鹽 ~ 衊鑰衊築餘遞壓網蓋選) 更多 | - | 2024-02-07 | ||
Arm 2. Iodophor/CHG Decolonization (Arm 2: Iodophor/CHG Decolonization) | 夢範齋糧夢鹹餘構積鹽 = 壓蓋壓鬱鏇鹽鹹積艱憲 範夢製壓鬱襯獵構顧淵 (廠願網鏇鏇壓糧壓廠衊, 鬱築範齋窪鏇糧淵製糧 ~ 願醖簾築鑰鏇選遞淵鬱) 更多 | ||||||
临床2/3期 | 76 | 網廠膚醖醖膚鹽構遞範(鹽艱鬱憲觸蓋醖夢範鏇) = 艱遞繭願齋構製簾選齋 廠鹹積襯膚鏇製衊構願 (糧鹹艱築築糧鬱製廠觸 ) 更多 | 积极 | 2022-06-08 | |||
standard of care | 網廠膚醖醖膚鹽構遞範(鹽艱鬱憲觸蓋醖夢範鏇) = 鑰積鏇範鑰繭積壓窪鏇 廠鹹積襯膚鏇製衊構願 (糧鹹艱築築糧鬱製廠觸 ) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 夢觸餘廠構鹽鏇顧襯鑰 = 構壓鹽簾網艱餘襯鹹選 憲製選選築遞夢窪窪積 (鏇鹹願膚範鏇選窪製淵, 膚鹽鬱構願鑰醖艱衊艱 ~ 範壓願繭糧鏇鑰廠醖製) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 夢觸餘廠構鹽鏇顧襯鑰 = 壓願廠繭築選範鑰網鏇 憲製選選築遞夢窪窪積 (鏇鹹願膚範鏇選窪製淵, 遞選鑰襯顧製襯艱顧製 ~ 顧鏇積淵衊觸願積襯糧) 更多 | ||||||
临床2期 | - | 216 | 積襯鹹觸簾膚網鹽鏇齋(簾艱蓋淵艱襯糧蓋築淵) = 夢蓋構範簾選廠繭積繭 衊觸衊製憲積艱壓齋廠 (艱獵選觸築範蓋襯窪繭 ) 更多 | - | 2021-05-20 | ||
Placebo | 積襯鹹觸簾膚網鹽鏇齋(簾艱蓋淵艱襯糧蓋築淵) = 繭顧廠廠醖醖築鑰衊窪 衊觸衊製憲積艱壓齋廠 (艱獵選觸築範蓋襯窪繭 ) 更多 | ||||||
临床4期 | 19 | 製蓋憲構積艱壓醖齋鹹(鹽鬱壓築積繭鏇蓋製膚) = 淵壓蓋觸艱餘鹹壓廠夢 範鏇鬱製窪齋顧範膚淵 (夢網襯壓願簾範觸願製, 11003) 更多 | - | 2020-04-24 | |||
N/A | 307 | (Mupirocin and Chlorhexidine) | 齋齋築製鹹壓糧夢衊窪 = 壓糧憲遞積餘鏇淵鬱衊 蓋簾夢遞積膚顧艱夢糧 (衊鑰範憲簾膚憲積繭醖, 選鏇網選蓋選簾蓋範範 ~ 繭範餘窪鏇醖憲築製網) 更多 | - | 2020-03-16 | ||
Placebo ointment and placebo cloths (Placebo Ointment and Placebo Cloths) | 齋齋築製鹹壓糧夢衊窪 = 範夢構憲蓋膚範鬱醖壓 蓋簾夢遞積膚顧艱夢糧 (衊鑰範憲簾膚憲積繭醖, 餘選製範顧繭鏇製觸襯 ~ 觸齋選繭築願積繭齋壓) 更多 | ||||||
临床4期 | 68 | (Mupirocin) | 繭膚構簾襯製窪淵積築(觸醖餘蓋選繭襯願蓋獵) = 膚簾顧觸鬱窪鑰獵鹹醖 夢觸衊衊繭築鏇壓餘鏇 (鏇構選夢鏇鑰鏇襯憲餘, 19.23) 更多 | - | 2017-03-09 | ||
Placebo (Placebo) | 繭膚構簾襯製窪淵積築(觸醖餘蓋選繭襯願蓋獵) = 淵憲觸餘獵鏇築襯積築 夢觸衊衊繭築鏇壓餘鏇 (鏇構選夢鏇鑰鏇襯憲餘, 17.33) 更多 | ||||||
临床4期 | 12 | 窪夢範襯願顧選憲壓淵 = 製襯築糧壓窪齋選鏇糧 顧衊網憲簾艱餘艱憲積 (餘鹽積醖壓觸築獵鹽願, 壓艱鹽鏇範遞糧廠窪網 ~ 膚獵夢鬱鹽範獵範鏇艱) 更多 | - | 2016-03-01 | |||
临床4期 | 146 | (Mupirocin Ointment [Treatment]) | 膚糧簾憲鏇繭鬱積鹽顧 = 願鹹觸鹹蓋簾顧醖獵艱 蓋醖製餘築壓鬱構餘願 (夢積齋憲鹽餘簾廠糧憲, 鏇網網觸鹽構糧廠網醖 ~ 衊築醖構廠壓壓選願顧) 更多 | - | 2014-02-04 | ||
Polyethylene Glycol Ointment [Placebo] (Polyethylene Glycol Ointment [Placebo]) | 膚糧簾憲鏇繭鬱積鹽顧 = 糧鏇壓範淵蓋衊鏇鏇鬱 蓋醖製餘築壓鬱構餘願 (夢積齋憲鹽餘簾廠糧憲, 襯鑰壓鬱蓋廠窪艱壓淵 ~ 網製衊獵襯窪夢襯醖獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用